Shanghai, China – December 15, 2025 – MicroPort CardioFlow Medtech Corporation (02160.HK, "MicroPort^® CardioFlow") announced that shareholders have approved its strategic merger with MicroPort^® Cardiac Rhythm Management ("MicroPort^® CRM"). Under the approved transaction, MicroPort^® CardioFlow will acquire MicroPort^® CRM through the issuance of new shares, with a total consideration of USD 680 million. The approval marks the final stage of this strategic merger.

The merger follows a comprehensive evaluation of both businesses' technological capabilities, research and development resources, and collaboration potential. Upon completion, the combined company will integrate complementary strengths across structural heart intervention and cardiac rhythm management. MicroPort^® CardioFlow brings established capabilities in passive implants and the design of transcatheter delivery systems, as well as profound expertise in hemodynamic platforms. MicroPort^® CRM contributes long-standing core expertise in the development of active implants, AI-enabled diagnostics, biological signal acquisition, algorithm development, and big data platforms.

Building on this foundation, the combined company will continue to optimize existing product pipelines while also establishing heart failure as a new core strategic focus. These three areas represent the new company's integrated platform spanning structural heart intervention, rhythm management, and heart failure care. By bringing together device-based therapies and continuous monitoring technologies, the company aims to develop an integrated heart failure management platform covering the entire cycle of monitoring, diagnosis, and treatment, with global reach. The post-merger synergies will enable the development of an integrated heart failure management platform covering all etiologies, disease stages, and the entire care cycle. This platform will provide comprehensive heart failure management services tailored to different pathogenic factors, disease phases, and the full spectrum of monitoring, diagnosis, treatment, and management.

Beyond this additional strategic focus, the merger is expected to strengthen the company's operational foundation and support sustainable and high-quality growth:

a) Portfolio Integration and Global Expansion: Product pipeline integration will enable a more comprehensive and rich product portfolio across structural heart disease and cardiac rhythm management, supporting broader hospital coverage and accelerating global market penetration through MicroPort^® CRM's mature sales channels.

b) Global Resource Alignment and Operational Synergies: The merger strengthens global collaboration across sales, distribution, and operational infrastructure. Leveraging MicroPort^® CRM's established operational teams and infrastructure is expected to improve localized operations in clinical development, quality systems, and customer support.

c) R&D Collaboration and Supply Chain Integration: Combined R&D capabilities will support deep technology integration and innovation. Supply chain integration will enhance economies of scale, strengthen resilience, and mitigate geopolitical and sourcing risks through diversified manufacturing and supplier networks.
 

Looking ahead, the combined company will establish integrated heart failure management as its core strategic focus. By fully leveraging the complementary strengths of both business lines in device-based therapies and continuous monitoring technologies, it aims to deliver innovative, end-to-end heart failure health management solutions for physicians and patients, and is committed to building a leading enterprise of emerging technologies in cardiac diagnosis and therapy.

About MicroPort^® CardioFlow

MicroPort^® CardioFlow is an innovation leader in the global structural heart disease interventional treatment field. It holds a leading position in the Chinese transcatheter aortic valve implantation (TAVI) market and has officially entered a new phase of scaled global operations and high-quality development. Through independent R&D and collaborative development with global partners, MicroPort^® CardioFlow has built a forward-looking innovative pipeline covering transcatheter solutions for aortic, mitral, and tricuspid valve diseases, interventional treatment for post-myocardial infarction ventricular septal defects, and stroke prevention related to atrial fibrillation, continuously leading industry technological innovation and global market expansion.

More information is available at: https://en.cardioflowmedtech.com/  

About MicroPort^® CRM:

MicroPort^® CRM is a global leader in the field of cardiac rhythm management, headquartered in Clamart, near Paris, France. With more than 60 years of expertise and continuous innovation, MicroPort^® CRM currently boasts 12 pipelines and over 40 marketed products across core cardiac rhythm management segments, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and Holter ECG diagnostic solutions.

More information is available at: www.microport.com

“This press release contains forward-looking statements regarding the expected benefits of the merger, future business plans, market expansion, product development, and integration synergies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could affect results include regulatory approvals, market conditions, integration challenges, and competitive dynamics. The companies undertake no obligation to update these forward-looking statements.”

Media Contact:

MicroPort^® CardioFlow ：wcxt@microport.com